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Summary: A time-saving protein binding assay for the simultaneous determination of cGMP and cAMP has been
adapted for human urine, using [3H]cGMP, [14C]cAMP, protein fractions from calf skeletal and lobster tail muscles
and the phosphodiesterase inhibitor SQ 20.009. Recovery, accuracy, and precision are approximately at the 10%
limit. Good specificity and no interference were observed with diluted urine samples (10 to 20 times).
Zeitsparende Proteinbindungsmethode für die simultane Bestimmung von Guanosin-3':5'-monophosphat (cGMP)
undAdenosin-3':5'-monophosphat (cAMP) im menschlichen Urin
Zusammenfassung: Eine zeitsparende Proteinbindungsmethode für die simultane Bestimmung von cGMP und cAMP
wurde für menschlichen Urin adaptiert; der Testansatz enthält [3H]cGMP, [14C]cAMP, Proteinfraktionen von Kalb-
skelettmuskel und Hummerschwanzmuskel sowie den Phosphodiesterasenhemmer SQ 20.009. Wiederauffindung,
Genauigkeit, Präzision liegen um die 10%-Grenze. Mit 10—20fach verdünnten Urinproben werden eine gute Spezifität
und keine Interferenz beobachtet.
Introduction
The determination of guanosine 3':5'-monophosphate
(cGMP) and adenosine 3':5'-rnonophosphate (cAMP) is
now performed routinely in many laboratories (1—3)
and there is an increasing demand for time-saving
simultaneous assays for both cyclic nucleotides (e. g.
in urine), with respect to their use in clinical diagnosis.
Recently two simultaneous protein binding assays have
been described, one using binding protein fractions
from bovine skeletal and lobster muscles (4), the other
using extracts from beef adrenal cortex and the fat
body of silkworm pupae (5). Both methods employ
*B- and 32P4abeled cyclic nucleotides in almost
equimolar concentrations; the latter isotope^ however,
is very unstable on account of its short halflife value.
Moreover, in the first procedure (4) the protein-nucleo-
tide complexes were collected on cellulose ester filters,
which requires a time consuming special filtration
technique; the second procedure (5) used the precipita-
tion technique with ammonium sulfate, which in turn
requires time consuming washing and transfer processes
for the protein-nucleotide complexes. Therefore in this
paper we describe a simple simultaneous protein binding
assay with stable 3HU and 14C-labeled cyclic nucleotides,
using the time saving charcoal absorption technique,
which requires only one centrifugation step. The assay
has been adapted for the concentrations of cAMP and
cGMP in human urine which exhibit a molar ratio of
5—10 to 1 (1—3). A preliminary report has been given
in I.e. (6).
Materials and Methods
All labeled compounds came from Amersham-Buchler, Braun-
schweig, and NEN, Dreieichenhain, G.F.R., and were declared
with a radio-chemical purity of 97-99%; [adenine-U-14ClcAMP
exhibits some chemical impurity of adenosine 5-monophosphate.
All cyclic nucleotides and biochemicals were perchased from
Boehringer, Mannheim, and the chemicals from E. Merck, Darm-
stadt, G.F.R. Norit A3 was obtained from Norit Clydesdale,
Glasgow, U. K.; it was suspended in double distilled water (l g
to 50 ml), centrifuged at 7800 £ and the residue dried for further
use. Bovine serum albumin was purchased from Behringwerke
Marburg/L. and treated (7) to remove lipids and fatty acids.
Urines of healthy persons were collected with theophylline
during 24 h and immediately analysed.
Preparation and characterization of binding proteins
cAMP and cGMP binding protein fractions were prepared
from calf skeletal muscle and from lobster tail muscle respec-
tively; they were further purified by chromatography on DEAE-
<cellulosc (Whatman DE 11) as described ((8) and (9), respec-
tively). The isolated peak II- and peak I-fractions were dialysed
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Total volume 0.15 ml, 0.25 pmol [3H(G)JcAMP (1421 TBq/mol = 38.4 Ci/mmol)), 2.65 μ§ binding protein fraction from calf
skeletal muscle. For further details see legend of fig. 3.
each at 4 °C against buffer (120 mmol/1 Tris-HCl, pH 7.4),
divided into 1 ml portions and stored at - 70 °C for several
months without significant loss of binding activity. The protein
fraction from calf skeletal muscle bound 0.2 pmol cAMP and
< 0.001 pmol cGMP per Mg protein (determined according to
1. c. (10) using bovine serum albumin as standard); the protein
fraction from lobster muscle bound 0.5 pmol cGMP and
0.045 pmol cAMP per mg protein after incubation with
14 nmol/1 cyclic (8-3H]cGMP (155 Τ Bq/mol (4.2 Ci/mmol)),
or 10 nmol/1 [3H(G)]cAMP (710 Τ Bq/mol (19.2 Ci/mmol)),
using the conditions and buffer D of table 1.
Results and Discussion
Conditions of the
simultaneous protein binding assay
Conditions similar those described byDinnendahl (11)
for the cGMP binding assay were used. Therefore the
conditions for the cAMP binding assay reported by
Brown et al. (12) had to be changed with respect to
the concentration of Tris-HCl buffer, which was in-
creased (table 1). Furthermore, MgSO4 was added and
the concentration of 2-mercaptoethanol increased.
Theophylline was replaced by SQ 20.009 (l-ethyl-4-
(isopropylidene-hydrazino)-l H-pyrazolol[3 ,-4-b]
pyridine-5-carboxylic acid, a kind gift from Squibb,
Princeton, N. J., U.S.A.), which is reported to inhibit
the phosphodiesterase activity sixty-fold more than
theophylline (13). Table 1 demonstrates that the
altered conditions (especially SQ 20.009) do not
influence significantly the amount of bound radio-
activity nor the apparent dissociation constant of
cAMP. Moreover, the conditions described with D
in table 1 yield the same binding data for cGMP as
are obtained with the Dinnendahl method (see below).
In order to evaluate optimal binding conditions,
binding curves with increasing amounts of labeled cAMP
or cGMP were established under the buffer conditions
D of table 1 (figs, la, b). The saturation value for
cAMP was established with 0.2 pmol/Mg protein and
for cGMP with 1.4 pmol/mg protein. Under these
conditions, the apparent dissociation constant of the
binding protein fraction from calf skeletal muscle was
between 2—4 nmol/1 cAMP (determined with
[3H(G)]cAMP (table 1) as well as with [adenine-U^14C]
cAMP (fig. Ib); and the protein from lobster muscle
gave a value between 5—10 nmol/1 cGMP (mean values
of 4 experiments), confirming the values described by
others (Ϊ1, 14, 15).
Having combined both fractions of binding protein for
the simultaneous assay, the apparent dissociation constant
increased about 10 to 20 times with respect to cAMP
binding and different charges of binding protein frac-
tions. This obviously unspecific effect, also described
for albumin (4,14), was not altered by adding increasing
amounts of cAMP. Under both conditions similar dose-
binding curves were obtained (fig. 2). The apparent
dissociation constant for cGMP was neither altered by
the presence of skeletal muscle binding protein (cf.
1. c. (4)), nor after the addition of 20 pmol or more
cAMP (e. g. [adenine-U-14C]cAMP). In both cases, the
dose-binding curves showed linear log-log plots with
slightly different slopes (fig. 2) indicating that
[14C]cAMP does not strongly interfere. The experimental
binding data resemble the competitive inhibition data
for an enzyme (which has nevertheless one and the
same saturation value (cf. 1. c. (16)). Moreover, under
these conditions log^log plots of the dose-binding
curves are linear for cAMP (rarige 200—1600 nmol/1)
and cGMP (range 5-160 nmol/1) in the simultaneous
binding assay (fig. 3).
The simultaneous protein binding assay for cGMP and
cAMP described here has, however, one important dis-
advantage in comparison to those using 32P-labeled
cyclic nucleotides (4, 5): only 5% of [adenine4J-14C]
cAMP offered in the test is bound, so that the radioactive
counts obtained are low, in contrast to those obtained
with [3H]cAMP and [3H]cGMP, which are bound to an
extent of more than 20%. The cause of the poor
[14C]cAMP binding remains unclear; contaminations
of large amounts of cold cAMP or cGMP appear to be
unlikely (fig. 2b, see above) and interferences with
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Fig. 1. Binding curves and double-reciprocal plots of cGMP and cAMP.
a) Increasing amounts of [8-3H)cGMP (777 TBq/mol (21 Ci/mmol)) were incubated for 2 h at 4 °C together with 440 Mg
binding protein fraction from lobster muscle.
b) Increasing amounts of [adenine-U-14C]cAMP (10.6 TBq/mol (287 mCi/mmol)) were incubated for 2 h at 4 °C together
with 1.6 Mg binding protein fraction from calf skeletal muscle. In both cases buffer conditions D of table 1 were used
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Fig. 2. Dqse^binding curves for cAMP and cGMP on protein frac-
tions from lobster muscle (G) and calf skeletal muscle (A).
a) o;—ο 5 Mg protein A, 200 Mg protein G, 0.5 pmol
[ribose-5-3H]cGMP (1.15 PBq/mol (31 Ci/mmol» plus
increasing amounts of cGMP as indicated on the cGMP
scale.
b) ·-*-· the same constituents as described under a) plus
20 pmol [adenine-lM4CJcAMP (10.6 TBq/mol
(287 mCi/mmol)); only increasing amounts of cGMP
were added as indicated on the cGMP scale for
[3HJcGMP as weil as on the cAMP scale for
[HC)cAMP, respectively.
c) Δ.—Δ 5 μ| protein A, 200 Mg protein G, 20 pmol
[adenine- -14C]cAMP plus increasing amounts of
cAMP as indicated on the cAMP scale.
d) A-^^A the same constituents as described under c)
plus 0.5 pmol [ribose-5-3HJcGMP. Only increasing
amounts of cAMP were added as indicated on the
cAMP scale for [<i4CJcAMP and on the cGMP scale
for [3H)cGMP, respectively.
Total volume 0.1 ml; buffer conditions as described





Fig. 3. Dose-binding curves for the simultaneous binding assay
for cGMP and cAMP.
Mean values ± S. D. from 5 experiments. To a total
volume of 100 M! were added 20 M! urine (diluted 10 to
20 times with buffer D, table 1), 0.5 pmol
[ribose-5-3H]cGMP (1.15 PBq/mol (31 Ci/mmol)),
20 pmol [adenine-U-14CJcAMP (10.6 TBq/mol
(287 mCi/mmol)) and buffer (conditions D of table 1);
after mixing, the reaction was started with 5 Mg binding
protein fraction from calf skeletal muscle plus 200 Mg
binding protein fraction from lobster muscle and in-
cubated for 2 h at 4 °C; blank without proteins, sample
volume 20 μΐ. Then 50 M! charcoal suspension (30 g/1
charcoal, 10 g/1 albumin in buffer D of table 1) were
added to all samples simultaneously which were
centrifuged at 2000 £ for 20 min at 4 °C. 100 M! clear
supernatant were mixed with 400 μΐ bidist. water in
10 ml Unisolve I (Zinsser*Frankfurt/M., G.F.R.) and
counted in a Tri-Carb model 3380 with automatic unit
model 544 (Packard Instruments, Frankfurt/M., G.F.R.)
with a counting error of less than 5 %.
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other nucleosides or nucleotides occur only with
higher concentrations (e. g. l mmol/1 adenosine-5-
monophosphate inhibited < 5% [3H]oAMP binding,
for further details see below).
Accuracy
The simultaneous recovery (n = 45) of 20 pmol cAMP
and 2 pmol cGMP in urine samples exhibits values be-
tween 89% and 111% and 92% and 108%, respectively.
Comparing the results of two urines measured by
individual binding assays for cGMP (cf. 1. c. (11)): 1000;
330 nmol/1) and for cAMP (cf. 1. c. (12)): 6.70;
2.90 μιτιοΐ/ΐ) with those determined by the simultaneous
binding assay (cGMP: 1050; 340 nmol/1; cAMP: 6.30;
2.80 jumol/l) the values are in accordance below the
10% limit. Furthermore, the data for two urines ob-
tained in the presence of both binding proteins corre-
spond well (below the 10% limit) with those measured
by the simultaneous binding assay: for cAMP: 6.26
(8.51) and 6.88 (8.23) μπιοΐ/ΐ; for cGMP: 585 (948)
and 594 (888) nmol/1.
Precision
The coefficient of variation from day to day (10 different
experiments) ranges between 8 to 10% for cGMP and
between 5 to 12% for cAMP, when both nucleotides
were estimated simultaneously in molar cGMP to cAMP
ratios of 1 to 2.5 and 1 to 40. Similar coefficients of
variation are exhibited by the recovery experiments
with a molar ratio of cyclic nucleotides of 1 to 20 as
demonstrated above. The coefficient of variation within
series shows somewhat lower values: 5 to 8% and 5 to
9%, respectively.
Specificity
Although, in the simultaneous assay, cAMP is bound
by two different binding protein fractions, log-log
plots of the dose-binding curves are linear, and they
do not show any disturbance with increasing concentra-
tions of cGMP (5-160 nmol/1, figs. 2, 3). 10 times
higher concentrations of cGMP begin to displace cAMP
from skeletal muscle binding protein. cGMP is only
bound by the protein fraction from lobster muscle;
however, cAMP concentrations > 400 nmol/1 begin to
displace labeled cGMP, thus exhibiting a 50 to 100
times higher value for the apparent dissociation con-
stant. Therefore urine samples have to be diluted 10 to
20 times with buffer Ρ (table 1); otherwise cGMP values
must be corrected (e. g.: 500 nmol/1 cAMP displace
~ 1.0 nmol/1 cGMP, 800 ~ 2.6,1600 ~* 6.8; conditions
of fig. 2). Nevertheless, in the diluted urine samples
the cGMP concentration appears to be high enougji for
its exact measurement.
Interference
Interference by corresponding purine bases, nucleosides
or nucleotides (e. g. adenosine-(guanosine^)mono-, di-,
triphosphate) occurs with 10 to 1000 times higher
concentrations than are to be expected in the test (cf.
1. c. (11, 12,15, 17)). To exclude a chemical .inter-
ference, individual blanks of the diluted urine samples
are used, and generally they have proved to be low.
Cyclic nucleotide levels in 12 human urines were
measured by the simultaneous binding assay (condi-
tions see fig. 3) and related to the urine volume excreted
during 24 h or to 1 mol creatinine (determined with
the Technicon Autoanalyzer). In 5 healthy men
(44 ± 9 years old) the value for cAMP was 6.73 ±
2.12 μπιοΙ/24 h (0.169 ± 0.043 mmol/mol creatinine)
and for cGMP 649 ± 179 nmol/24 h (16.3 ±
3.2 μπιοΐ/rri l creatinine), in 7 healthy women (38 ±
12 years old) 5.51 ± 1.03 (0.191 ± 0.047) and 648 ±
219 (22.6 ± 6.2). The data correspond well with those
determined by other procedures (cf. 1. c. (1, 3, 14)).
Summing up, although the counting (and binding)
yields are low with respect to [14C]cAMP, the precision,
accuracy and recovery of the simple simultaneous
protein binding assay adapted for human urine are
quite satisfactory for cAMP and cGMP, and they are
comparable to those of other individual or simultaneous
techniques already described (1, 3,14; 4). The time-
saving assay (up to 50 samples may be analysed in
triplicate per day) appears to considerably lower the
cost, compared with commercially available individual
protein binding assays.
Note added to the proof:
Using other batches of iU-1^Giadenine]cAMP and binding protein
fractions of lobster tau muscles 9 to 15% of [U-14C-adenine]cAMP
offered in the test are bound, so that the radioactive counts
obtained are at least two times higher than described, indicating
now a better sensitivity of the test.
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